A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT06772779
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Warfarin — DRUG
    single oral dose
  • Enlicitide Decanoate — DRUG
    single oral dose
  • Lisinopril — DRUG
    single oral dose

Study Details

The main goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate with warfarin or lisinopril. Researchers want to learn if the amount of warfarin in a person's blood is similar when warfarin is taken alone or with enlicitide decanoate. Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Warfarin is a drug that reduces risk of blood clotting, and lisinopril is a drug that lowers blood pressure.

Key Dates

Start date
Apr 1, 2024
Status verified
Jan 2025
Primary completion
Jun 4, 2024
Completion
Jun 4, 2024

Study Design

Enrollment
36 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Warfarin Plus Enlicitide Decanoate
    Participants receive oral warfarin and oral enlicitide decanoate.
  • Experimental: Lisinopril Plus Enlicitide Decanoate
    Participants receive oral lisinopril and oral enlicitide decanoate.

Primary Outcome Measure

Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Warfarin [ Time Frame: At designated timepoints (up to approximately 2 weeks postdose) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion (Site 0001)TempeArizona85283-

Find similar trials in Tempe, AZ

By research site
Celerion· Tempe, AZ

Related Studies